Get the Stockscreener App
0.6896
6.81%
-0.0504
After Hours:
.68
-0.0096
-1.39%
Maxcyte Inc stock is traded at $0.6896, with a volume of 1.95M.
It is down -6.81% in the last 24 hours and down -13.36% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$0.74
Open:
$0.73
24h Volume:
1.95M
Relative Volume:
1.84
Market Cap:
$73.56M
Revenue:
$34.42M
Net Income/Loss:
$-45.63M
P/E Ratio:
-1.6045
EPS:
-0.4298
Net Cash Flow:
$-41.23M
1W Performance:
-5.66%
1M Performance:
-13.36%
6M Performance:
-54.93%
1Y Performance:
-77.75%
1-Day Range:
$0.676
$0.7426
1-Week Range:
$0.676
$0.80
52-Week Range:
$0.6434
$3.10
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
0.6896 | 78.94M | 34.42M | -45.63M | -41.23M | -0.4298 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-22-25 | Initiated | Stephens | Overweight |
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
MaxCyte 2025 10‑K: Revenue $33.0M, EPS $(0.42) - TradingView
MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside - Stock Titan
MXCT: Craig-Hallum Maintains Buy Rating but Lowers Price Target - GuruFocus
Craig Hallum Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - MarketBeat
Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds - Investing.com
Stifel cuts MaxCyte stock price target on 2026 revenue guidance - Investing.com UK
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 earnings call transcript - MSN
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 Earnings Call Transcript - Insider Monkey
MaxCyte 2025 Financial Results Review - AlphaStreet
MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1 - Minichart
MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ... By GuruFocus - Investing.com Canada
MaxCyte, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
MaxCyte, Inc. (MXCT) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - The Globe and Mail
MaxCyte Q4 Earnings Call Highlights - MarketBeat
MaxCyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance Australia
Earnings call transcript: MaxCyte Q4 2025 misses earnings, revenue forecasts - Investing.com
Earnings call transcript: MaxCyte Q4 2025 misses earnings, revenue forecasts By Investing.com - Investing.com India
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook - TipRanks
MaxCyte Inc. (MXCT) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
MaxCyte (NASDAQ:MXCT) Issues Earnings Results - MarketBeat
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance - The Manila Times
MaxCyte (NASDAQ: MXCT) 2025 revenue falls and company issues 2026 outlook - Stock Titan
MaxCyte, Inc. Reports Goodwill Impairment for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
MaxCyte stock rating reiterated at Market Perform by William Blair - Investing.com UK
MaxCyte, Inc. Appoints Parmeet Ahuja as Chief Financial Officer, Effective March 30, 2026 - marketscreener.com
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer - The Manila Times
MaxCyte appoints Parmeet Ahuja as chief financial officer - marketscreener.com
Maxcyte Appoints Parmeet Ahuja As Chief Financial Officer - TradingView
Agilent investor relations veteran Parmeet Ahuja joins MaxCyte as CFO - Stock Titan
MaxCyte (NASDAQ:MXCT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition - AOL.com
MaxCyte (MXCT) Stephens 26th Annual Investment Conference | NASH2024 Summary - Quartr
Analyst Upgrade: Is now the right time to enter MaxCyte IncMarket Growth Summary & Weekly Market Pulse Updates - baoquankhu1.vn
MaxCyte receives Nasdaq notice for non-compliance with minimum bid price - Investing.com India
Form 8K MaxCyte Inc For: 20 March - Investing.com
Form 8K MaxCyte Inc For: 20 March By Investing.com - Investing.com Canada
MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price - TipRanks
MaxCyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
MaxCyte (NASDAQ: MXCT) faces Nasdaq $1 bid-price deficiency and delisting risk - Stock Titan
MaxCyte (MXCT) launches ExPERT DTx platform to accelerate high-throughput drug discovery - MSN
MaxCyte (MXCT) CFO covers RSU tax withholding through automatic share sale - Stock Titan
MaxCyte, Inc. $MXCT Shares Bought by Mirabella Financial Services LLP - MarketBeat
Aug Setups: Is MaxCyte Inc showing insider buyingDip Buying & Daily Entry Point Alerts - baoquankhu1.vn
Buybacks Report: What is the next catalyst for MaxCyte Inc2026 Big Picture & Verified Trade Idea Suggestions - baoquankhu1.vn
Mirabella Financial Services LLP Purchases 1,600,000 Shares of MaxCyte, Inc. $MXCT - MarketBeat
MaxCyte (MXCT) Projected to Post Earnings on Tuesday - MarketBeat
MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Risk Check: Should I average down on MaxCyte Inc stock2026 WrapUp & Daily Profit Focused Screening - baoquankhu1.vn
Insider Sell: Will MaxCyte Inc outperform tech stocksInflation Watch & High Conviction Buy Zone Alerts - baoquankhu1.vn
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):